Transarterial chemoembolization in pancreatic adenocarcinoma with liver metastases: MR-based tumor response evaluation, apparent diffusion coefficient (ADC) patterns, and survival rates

Vogl, Thomas J.; Mohamed, Sherif A.; Albrecht, Moritz H.; Gruber-Roh, Tatjana; Lin, Han; Nour-Eldin, Nour-Eldin A.; Bednarova, Iliana; Naguib, N; Panahi, Bita

doi:10.1016/j.pan.2017.11.014

Cited by 22 publications

(21 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the clinic, transarterial chemoembolization (TACE) is a first‐line therapeutic option for HCC treatment, and multiple chemotherapeutic drugs have been used in TACE, such as mitomycin and camptothecin . To determine whether reducing KIF20B sensitizes HCC cells to these chemotherapeutic drugs, we detected the viability of HepG2, Hep3B and HuH‐7 cells treated with Ad‐shKIF20B and hydroxycamptothecin or mitomycin C. Results suggested that shKIF20B increased the toxicity of hydroxycamptothecin or mitomycin C (Figure A).…”

Section: Resultsmentioning

confidence: 99%

“…In the clinic, transarterial chemoembolization (TACE) is a first-line therapeutic option for HCC treatment, and multiple chemotherapeutic drugs have been used in TACE, such as mitomycin and camptothecin. 33 To determine whether reducing KIF20B sensitizes HCC F I G U R E 3 Adenoviral vector expressing shRNAs targeting kinesin family member 20B (Ad-shKIF20B) blocks mitotic exit of HepG2 cells at telophase. A, MTT results 72 h after indicated treatments.…”

Section: Reducing Kif20b Sensitizes Hcc Cells To Two Chemotherapeutmentioning

confidence: 99%

See 1 more Smart Citation

Inhibition of kinesin family member 20B sensitizes hepatocellular carcinoma cell to microtubule‐targeting agents by blocking cytokinesis

Liu

Zhang

et al. 2018

Cancer Science

View full text Add to dashboard Cite

Kinesin family member 20B (KIF20B, also known as MPHOSPH1) is a kinesin protein that plays a critical role in cytokinesis. Previously, we and others have demonstrated the oncogenic role of KIF20B in several cancers; however, the exact mechanisms underlying its tumorigenic effects remain unclear. Herein, we showed overexpression of KIF20B in human hepatocellular carcinoma (HCC) and reported a negative correlation between KIF20B level and prognosis of patients. Mechanistically, reducing KIF20B blockades mitotic exit of HCC cells at telophase in a spindle assembly checkpoint independent way. Importantly, reducing KIF20B acts synergistically with three microtubule‐associated agents (MTA) to p53‐ or p14ARF‐dependently suppress p53‐wt or p53‐null HCC cells. In addition to taxol, reducing KIF20B also enhanced the toxicity of two chemotherapeutic drugs, hydroxycamptothecin and mitomycin C. In conclusion, we found a novel mechanism in that blocking cytokinesis by KIF20B inhibition increases the efficacy of MTA; our results thus suggested a dual‐mitotic suppression approach against HCC by combining MTA with KIF20B inhibition, which simultaneously blocks mitosis at both metaphase and telophase.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Reducing Kif20b Sensitizes Hcc Cells To Two Chemotherapeutmentioning

confidence: 99%

Inhibition of kinesin family member 20B sensitizes hepatocellular carcinoma cell to microtubule‐targeting agents by blocking cytokinesis

Liu

Zhang

et al. 2018

Cancer Science

View full text Add to dashboard Cite

show abstract

“…In cases of hepatocellular carcinoma (HCC), a complete response of 23% and objective response of 66% as well as an improvement in survival can be observed after TACE. 82 , 83 When treating malignant liver metastases, a partial response rate up to 56% in the case of liver metastasis with neuroendocrine tumors (stable disease 40%), 84 partial response up to 11.5% in the case of liver metastases from pancreatic cancer (stable disease 78%), 85 and partial response up to 80% in the case of colorectal liver metastases (stable disease up to 48%) 86 were reported. As both therapy concepts are based on locoregional application of cytostatic in hepatocellular parenchyma, a similar response rate of ECT by liver lesions can be possible.…”

Section: Electrochemotherapy In Clinical Practicementioning

confidence: 99%

Electrochemotherapy as a New Modality in Interventional Oncology: A Review

Probst

Fuhrmann

Beyer

et al. 2018

Technol Cancer Res Treat

132

111

View full text Add to dashboard Cite

Electroporation is a well-known phenomenon that occurs at the cell membrane when cells are exposed to high-intensity electric pulses. Depending on electric pulse amplitude and number of pulses, applied electroporation can be reversible with membrane permeability recovery or irreversible. Reversible electroporation is used to introduce drugs or genetic material into the cell without affecting cell viability. Electrochemotherapy refers to a combined treatment: electroporation and drug injection to enhance its cytotoxic effect up to 1000-fold for bleomycin. Since several years, electrochemotherapy is gaining popularity as minimally invasive oncologic treatment. The adoption of electrochemotherapy procedure in interventional oncology poses several unsolved questions, since suitable tumor histology and size as well as therapeutic efficacy still needs to be deepen. Electrochemotherapy is usually applied in palliative settings for the treatment of patients with unresectable tumors to relieve pain and ameliorate quality of life. In most cases, it is used in the treatment of advanced stages of neoplasia when radical surgical treatment is not possible (eg, due to lesion location, size, and/or number). Further, electrochemotherapy allows treating tumor nodules in the proximity of important structures like vessels and nerves as the treatment does not involve tissue heating. Overall, the safety profile of electrochemotherapy is favorable. Most of the observed adverse events are local and transient, moderate local pain, erythema, edema, and muscle contractions during electroporation. The aim of this article is to review the recent published clinical experiences of electrochemotherapy use in deep-seated tumors with particular focus on liver cases. The principle of electrochemotherapy as well as the application to cutaneous metastases is briefly described. A short insight in the treatment of bone metastases, unresectable pancreas cancer, and soft tissue sarcoma will be given. Preclinical and clinical studies on treatment efficacy with electrochemotherapy of hepatic lesions and safety of the procedure adopted are discussed.

show abstract

“…A previous study showed that in patients with pancreatic cancer, arterial infusion chemotherapy was able to achieve a drug concentration several times higher than intravenous administration, thereby accomplishing the goal of direct antitumor effects. 19 In our current study, arterial chemoembolization was performed one day before 125 I particle implantation. Compared with conventional systemic chemotherapy and radiation treatment, our combined therapy targets the bone tumor site more selectively by localized administration of chemotherapeutic agent and radiation particles.…”

mentioning

confidence: 99%

Iodine-125 seed implantation combined with arterial chemoembolization therapy for pain palliation in metastatic bone cancer: a retrospective study

Yang

Chen

Cui

et al. 2018

Cancer Biology & Therapy

View full text Add to dashboard Cite

Bone metastases are the most common sites for malignant tumors. Patients who failed to respond to initial first-line treatment with bisphosphonates usually suffer from extreme pain. The aim of this study was to observe the efficacy of arterial chemoembolization combined with Iodine-125 seed implantation in the treatment of bone metastatic cancer pain. All 14 patients with metastatic bone tumor wo failed first-line treatment underwent arterial chemoembolization the day before the implantation of the particles. A computer stereoscopic TPS was used to design the treatment plans, the number and dose of particles required for implantation. Pain relief was evaluated using several parameters such as Visual Analog Scale (VAS) and Verbal Rating Scales (VRS). Pain intensity was measured pre-operation and 1-week, 1-month, 3month after the treatment. Meanwhile, we also assessed tumor size using computer tomography (CT). Pain palliation was observed in 35.7% (5/14), 57.1% (8/14), and 78.6% (11/14) of all patients at 1-week, 1-month and 3-month post treatment. Likewise, our analysis showed that the combination therapy resulted in a significant decrease of VAS score (6.71 ± 0.49 before treatment vs 3.36 ± 0.40 at 3 month post treatment) and overall responding rate of 92.0% using VRS pain assessment. Consistently, tumor size was reduced from 42.16 ± 10.32 before treatment to 29.11 ± 8.73 at 3 months post treatment. No serious complications were detected. Our study demonstrate that the combination of arterial chemoembolization and 125 I particles resulted in evident pain relief and reduction of tumor burden, suggesting that the combination treatment could be a feasible and promising therapy for bone tumor management.

show abstract

Transarterial chemoembolization in pancreatic adenocarcinoma with liver metastases: MR-based tumor response evaluation, apparent diffusion coefficient (ADC) patterns, and survival rates

Cited by 22 publications

References 18 publications

Inhibition of kinesin family member 20B sensitizes hepatocellular carcinoma cell to microtubule‐targeting agents by blocking cytokinesis

Inhibition of kinesin family member 20B sensitizes hepatocellular carcinoma cell to microtubule‐targeting agents by blocking cytokinesis

Electrochemotherapy as a New Modality in Interventional Oncology: A Review

Iodine-125 seed implantation combined with arterial chemoembolization therapy for pain palliation in metastatic bone cancer: a retrospective study

Contact Info

Product

Resources

About